Vaccination Against Pathogenic Cells by DNA Inoculation

  • B. Wang
  • A. P. Godillot
  • M. P. Madaio
  • D. B. Weiner
  • W. V. Williams
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 226)


The goal of vaccination is to induce immunity to protect the host from disease. Vaccines should generate long-term protective immune responses which perform immune surveillance against specific antigens. Currently, a wide spectrum of vaccines are under development against not only infectious diseases, but also against cancers as well as allergic and autoimmune diseases. The mechanisms by which vaccines elicit protective immune responses against tumor growth have not been completely understood. Costimulatory molecule activation and strong cytolytic T cells (CTLs) have been implicated in the control of tumor cell growth or metastasis. Specific monoclonal antibodies have been also shown to control tumor cell growth to some degree. To achieve protective immune responses against tumor cells, we need to understand the context of the different cellular, humoral and molecular functions of the immune system.


Rabies Virus Antitumor Immunity Protective Immune Response Pathogenic Cell Gene Inoculation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agadjanyan MG, Wang B, Ugen KE, Villafana T, Merva M, Petrushina I, Williams WV and Weiner DB (1994) DNA inoculation with an HTLV-I envelope construct elicits immune responses in rabbits. Vaccines 94:47–53Google Scholar
  2. Brunda MJ, Luistro L, Rumennik L, Wright RB, Dvorozniak M, Aglione A, Wigginton JM, Wiltrout RH, Hendrzak JA and Palleroni AV (1996) Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol 38 Suppl:S16–21PubMedCrossRefGoogle Scholar
  3. Campbell MJ, Esserman L, Byars NE, Allison AC and Levy R (1990) Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 145:1029–36PubMedGoogle Scholar
  4. Ciernik IF, Berzofsky JA and Carbone DP (1996) Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 156:2369–75PubMedGoogle Scholar
  5. Conry RM, LoBuglio AF, Kantor J, Schlom J, Loechel F, Moore SE, Sumerel LA, Barlow DL, Abrams S and Curiel DT (1994) Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 54:1164–8PubMedGoogle Scholar
  6. Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL and Curiel DT (1995) A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 2:59–65PubMedGoogle Scholar
  7. Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G and Eck SL (1995) B7-l and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 55:4980–7PubMedGoogle Scholar
  8. Davis HL, Michel M-L and Whalen RG (1993) DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Human Mol Genetics 2:1847–1851CrossRefGoogle Scholar
  9. Dranofï G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting antitumor immunity (Meeting abstract). Gene Therapy for Neoplastic Diseases June 26–29, 1993, Washington, DC, AGoogle Scholar
  10. Fidler IJ (1978) Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 38:2651–60PubMedGoogle Scholar
  11. Gajewski TF (1996) B7-1 but not B7-2 efficiently costimulates CD8 + T lymphocytes in the P815 tumor system in vitro. J Immunol 156:465–72PubMedGoogle Scholar
  12. Gajewski TF, Fallarino F, Uyttenhove C and Boon T (1996) Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor:superiority of B7-l over B7-2 for active tumor immunization. J Immunol 156:2909–17PubMedGoogle Scholar
  13. Guo HG, Veronese F, Tschachler E, Pal R, Gallo RC and Reitz MS (1989) Characterization of an HIV-1 point mutation blocked in envelope glycoprotein cleavage. V. International conference on AIDSGoogle Scholar
  14. Hayashi H, Matsubara H, Yokota T, Kuwabara I, Kanno M, Koseki H, Isono K, Asano T and Taniguchi M (1992) Molecular cloning and characterization of the gene encoding mouse melanoma antigen by cDNA library transfection. J Immunol 149:1223–9PubMedGoogle Scholar
  15. Hom RC, Finberg RW, Mullaney S and Ruprecht RM (1991) Protective cellular retroviral immunity requires both CD4 and CD8 immune T cells. J Virol 65:220–224PubMedGoogle Scholar
  16. Irvine KR, Rao JB, Rosenberg SA and Restifo NP (1996) Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156:238–45PubMedGoogle Scholar
  17. Kieber-Emmons T, Jameson B and Morrow W (1989) The gpl20-CD4 interface:structural, immunological and pathological considerations. Biochim Biophys Acta 989:281–300PubMedGoogle Scholar
  18. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD and Weiner DB (1997) In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 158:816–826PubMedGoogle Scholar
  19. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N and Glimcher LH (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways:application to autoimmune disease therapy. Cell 80:707–18PubMedCrossRefGoogle Scholar
  20. Lafreniere R and Rosenberg SA (1985a) Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 135:4273–80PubMedGoogle Scholar
  21. Lafreniere R and Rosenberg SA (1985b) Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45:3735–41PubMedGoogle Scholar
  22. Liu B, Podack ER, Allison JP and Malek TR (1996) Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol 156:1117–25PubMedGoogle Scholar
  23. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R and Irie RF (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine [published erratum appears in Ann Surg 1993 Mar; 217(3): 309]. Ann Surg 216:463–82PubMedCrossRefGoogle Scholar
  24. Nabel EG, Plautz G and Nabel GJ (1990) Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 249:1285–1288PubMedCrossRefGoogle Scholar
  25. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D and Chang AE (1993) Direct gene transfer with liposome-DNA complexes in melanoma:expression, biological activity and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307–11311PubMedCrossRefGoogle Scholar
  26. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L and Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90:4645–4649PubMedCrossRefGoogle Scholar
  27. Raz E, Watanabe A, Baird SM, Eisenberg RA, Parr TB, Lotz M, Kipps TJ and Carson DA (1993) Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci USA 90:4523–7PubMedCrossRefGoogle Scholar
  28. Robinson HL, Fynan EF and Webster RG (1993) Use of direct DNA inoculations to elicit protective immune responses. Vaccines 93 Cold Spring Harbor Press:311–315Google Scholar
  29. Ruprecht MR, Mullaney S, Bernard LD, Sosa MAG, Horn RC and Finberg RW (1990) Vaccination with a live retrovirus:The nature of the protective immune response. PNAS 87:5558–5562PubMedCrossRefGoogle Scholar
  30. Syrengelas AD, Chen TT and Levy R (1996) DNA immunization induces protective immunity against B cell lymphoma. Nat Med 2:1038–41PubMedCrossRefGoogle Scholar
  31. Tang D-C, DeVit M and Johnston SA (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356:152–154PubMedCrossRefGoogle Scholar
  32. Tao M-H and Levy R (1993) Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B cell lymphoma. Nature 362:755–758PubMedCrossRefGoogle Scholar
  33. Tepper RI, Pattengale PK and Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503–512PubMedCrossRefGoogle Scholar
  34. Townsend SE, Su FW, Atherton JM and Allison JP (1994) Specificity and longevity of antitumor immune responses induced by B7- transfected tumors. Cancer Res 54:6477–83PubMedGoogle Scholar
  35. Trinchieri G (1995) Interleukin-12:a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251–76PubMedCrossRefGoogle Scholar
  36. Ullrich SJ, Robinson EA, Law LW, Willingham M and Appella E (1986) A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc Natl Acad Sci USA 83:3121–5PubMedCrossRefGoogle Scholar
  37. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Feigner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, Hawe LA, Leander KR, Martinez D, Perry HC, Shiver JW, Montgomery DL and Liu M (1993) Heterologous protection against Influenza by injection of DNA encoding a viral protein. Science 259:1745–1749PubMedCrossRefGoogle Scholar
  38. Wakabayashi S, Taniguchi M, Tokuhisa T, Tomioka H and Okamoto S (1981) Cytotoxic T lymphocytes induced by syngeneic mouse melanoma cells recognize human melanomas. Nature 294:748–750PubMedCrossRefGoogle Scholar
  39. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K and Hamada H (1996) Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 56:1828–33PubMedGoogle Scholar
  40. Wang B, Boyer J, Srikantan V, Coney L, Carrano R, Phan C, Merva M, Dang K, Agadjanyan M, Gilbert L, Ugen K, Williams VW and Weiner DB (1993) DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA Cell Biol 12:799–805PubMedCrossRefGoogle Scholar
  41. Wang B, Merva M, Dang K, Ugen KE, Williams WV and Weiner DB (1995) Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Human Gene Therapy 6:407–418PubMedCrossRefGoogle Scholar
  42. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Sato AI, Refaeli Y, Boyer J, Williams WV and Weiner DB (1993) Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90:4156–4160PubMedCrossRefGoogle Scholar
  43. Williams WV, Boyer JD, Merva M, LiVolsi V, Wilson D, Wang B and Weiner DB (1993) Genetic infection induces protective in vivo immune responses. DNA Cell Biol 12:675–683PubMedCrossRefGoogle Scholar
  44. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A and Feigner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468PubMedCrossRefGoogle Scholar
  45. Xiang ZQ, Spitalnik SL, Cheng J, Erikson J, Wojczyk B and Ertl HC (1995) Immune responses to nucleic acid vaccines to rabies virus. Virology 209:569–79PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • B. Wang
    • 1
  • A. P. Godillot
    • 2
    • 4
  • M. P. Madaio
    • 2
  • D. B. Weiner
    • 3
    • 4
  • W. V. Williams
    • 2
    • 4
    • 5
  1. 1.Sinogen Institute, Institute of ZoologyChinese Academy of SciencesBeijingPeoples Republic of China
  2. 2.Department of Medicine, Rheumatology DivisionUniversity of Pennsylvania School of Medicine, 912 Stellar-Chance LaboratoriesPhiladelphiaUSA
  3. 3.The Department of Pathology and Laboratory MedicineUniversity of Pennsylvania School of Medicine, 505 Stellar-Chance LaboratoriesPhiladelphiaUSA
  4. 4.Department of Biotechnology, Institute for Biotechnology and Advanced Molecular MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  5. 5.Childrens’ Hospital of PhiladelphiaPhiladelphiaUSA

Personalised recommendations